Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial

被引:0
|
作者
Westenbrink, B. Daan [1 ]
Alings, Marco [2 ]
Connolly, Stuart [3 ,4 ]
Eikelboom, Iohn [5 ]
Ezekowitz, Michael D. [6 ]
Oldgren, Jonas [5 ]
Yang, Sean [3 ,4 ]
Pogue, Janice [3 ,4 ]
Yusuf, Salim [3 ,4 ]
Wallentin, Lars [7 ]
van Gilst, Wiek H. [1 ]
机构
[1] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[2] Amphia Hosp, Breda, Netherlands
[3] Populat Hlth Rsch Inst, Hamilton, ON, Canada
[4] McMaster Univ, Hamilton, ON, Canada
[5] Uppsala Univ, Uppsala Clin Rsch Cntr, Uppsala, Sweden
[6] Lankenau Inst Med Res & Heart Cntr, Wynnewood, PA USA
[7] Uppsala Univ, Uppsala, Sweden
关键词
Anticoagulants; Hemoglobin; Myocardial Infraction; Outcomes;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
18466
引用
收藏
页数:2
相关论文
共 50 条
  • [41] DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS
    Flaker, Greg C.
    Reilly, Paul
    Yusuf, Salim
    Ezekowitz, Mike
    Wallentin, Lars
    Brueckmann, Martina
    Connolly, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E62 - E62
  • [43] Reduced Cerebral Bleeding Rates with Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation: Results of RE-LY
    Diener, Hans-Christoph
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Pogue, Janice
    Wallentin, Lars
    Reilly, Paul A.
    Yusuf, Salim
    NEUROLOGY, 2010, 74 (09) : A281 - A281
  • [44] Dabigatran better than warfarin in patients with atrial fibrillation and stroke risk - RE-LY study.
    Gadomska, Lucja
    KARDIOLOGIA POLSKA, 2009, 67 (10) : 1151 - 1152
  • [45] DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS
    Oldgren, Jonas
    Ezekowitz, Michael D.
    Alings, Marco
    Diener, Hans-Christoph
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    Connolly, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E7 - E7
  • [46] Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)
    Millenaar, Dominic
    Schumacher, Helmut
    Brueckmann, Martina
    Eikelboom, John W.
    Ezekowitz, Michael
    Slawik, Jonathan
    Ewen, Sebastian
    Ukena, Christian
    Wallentin, Lars
    Connolly, Stuart
    Yusuf, Salim
    Bohm, Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 149 : 27 - 35
  • [47] Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial
    Hori, Masatsugu
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION JOURNAL, 2011, 75 (04) : 800 - 805
  • [48] Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice
    Heidbuchel, Hein
    Verhamme, Peter
    ACTA CARDIOLOGICA, 2010, 65 (05) : 491 - 497
  • [49] Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
    McAlister, Finlay A.
    Mian, Rajibul
    Oldgren, Jonas
    Wallentin, Lars
    Ezekowitz, Michael
    Yusuf, Salim
    Connolly, Stuart J.
    Healey, Jeff S.
    PLOS ONE, 2020, 15 (01):
  • [50] Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis
    Kloosterman, Marielle
    Oldgren, Jonas
    Conen, David
    Wong, Jorge A.
    Connolly, Stuart J.
    Avezum, Alvaro
    Yusuf, Salim
    Ezekowitz, Michael D.
    Wallentin, Lars
    Ntep-Gweth, Marie
    Joseph, Philip
    Barrett, Tyler W.
    Tanosmsup, Supachai
    McIntyre, William F.
    Lee, Shun Fu
    Parkash, Ratika
    Amit, Guy
    Grinvalds, Alex
    Van Gelder, Isabelle C.
    Healey, Jeff S.
    EUROPACE, 2020, 22 (06): : 870 - 877